Literature DB >> 11014620

Clinical manifestations and molecular epidemiology of late recurrent candidemia, and implications for management.

C J Clancy1, F Barchiesi, L Falconi DiFrancesco, A J Morris, D R Snydman, V L Yu, G Scalise, M H Nguyen.   

Abstract

The aim of this study was to define the epidemiology and clinical manifestations of late recurrent candidemia. For this purpose, late recurrent candidemia was defined as an episode of candidemia occurring at least 1 month after the apparent complete resolution of an infectious episode caused by the same Candida sp. A total of five patients with recurrent candidemia were investigated. For all patients, isolates from the initial and recurrent episodes of candidemia were available for in vitro susceptibility testing and genetic characterization by DNA-based techniques. The results revealed the following salient features: prolonged duration between the initial and recurrent episodes (range, 1-8 months); recurrence of candidemia despite anti-fungal therapy; importance of retained intravascular catheters, neutropenia, and corticosteroids as factors predisposing to recurrence; high morbidity and mortality; no emergence of antifungal drug resistance between the initial and recurrent episodes; and relapse of infection due to the original infecting strain, rather than reinfection with a new strain. These findings raise several issues about the management and follow-up of patients with candidemia, which require assessment in future studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014620     DOI: 10.1007/s100960000335

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Candidemia in Norway (1991 to 2003): results from a nationwide study.

Authors:  Per Sandven; Lars Bevanger; Asbjørn Digranes; Hanne H Haukland; Turid Mannsåker; Peter Gaustad
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  A case of recurrent episodes of Candida parapsilosis fungemia.

Authors:  Dionissios Neofytos; Michael A Pfaller; Daniel J Diekema; David Horn
Journal:  Mycopathologia       Date:  2006-10       Impact factor: 2.574

3.  Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.

Authors:  William W Hope; George L Drusano; Caroline B Moore; Andrew Sharp; Arnold Louie; Thomas J Walsh; David W Denning; Peter A Warn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

Review 4.  Central venous catheter (CVC) removal for patients of all ages with candidaemia.

Authors:  Susanne Janum; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2016-07-11

5.  Candidemia in non-ICU surgical wards: Comparison with medical wards.

Authors:  Antonio Vena; Emilio Bouza; Maricela Valerio; Belén Padilla; José Ramón Paño-Pardo; Mario Fernández-Ruiz; Ana Díaz Martín; Miguel Salavert; Alessandra Mularoni; Mireia Puig-Asensio; Patricia Muñoz
Journal:  PLoS One       Date:  2017-10-18       Impact factor: 3.240

6.  Anidulafungin in the treatment of invasive fungal infections.

Authors:  Kathryn Sabol; Tawanda Gumbo
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.